These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 18173815)
1. Pain prevalence and treatment in patients with metastatic bone disease. Vieira C; Fragoso M; Pereira D; Medeiros R Oncol Lett; 2019 Mar; 17(3):3362-3370. PubMed ID: 30867771 [TBL] [Abstract][Full Text] [Related]
2. A Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin. Choudhury K; Dasgupta P; Paul N; Choudhury KB; Roy B; Maity S Indian J Palliat Care; 2018; 24(4):500-504. PubMed ID: 30410265 [TBL] [Abstract][Full Text] [Related]
3. Buprenorphine for treating cancer pain. Schmidt-Hansen M; Bromham N; Taubert M; Arnold S; Hilgart JS Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009596. PubMed ID: 25826743 [TBL] [Abstract][Full Text] [Related]
4. Toward a systematic approach to opioid rotation. Smith HS; Peppin JF J Pain Res; 2014; 7():589-608. PubMed ID: 25378948 [TBL] [Abstract][Full Text] [Related]
5. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. Skaer TL J Pain Res; 2014; 7():495-503. PubMed ID: 25170278 [TBL] [Abstract][Full Text] [Related]
6. Pain management in patients with cancer: focus on opioid analgesics. Leppert W Curr Pain Headache Rep; 2011 Aug; 15(4):271-9. PubMed ID: 21479998 [TBL] [Abstract][Full Text] [Related]
7. Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. Andresen T; Staahl C; Oksche A; Mansikka H; Arendt-Nielsen L; Drewes AM Br J Pharmacol; 2011 Oct; 164(3):934-45. PubMed ID: 21182491 [TBL] [Abstract][Full Text] [Related]
8. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Mercadante S; Casuccio A; Tirelli W; Giarratano A Support Care Cancer; 2009 Jun; 17(6):715-8. PubMed ID: 19104845 [TBL] [Abstract][Full Text] [Related]
9. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481 [TBL] [Abstract][Full Text] [Related]
10. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Likar R; Krainer B; Sittl R Int J Clin Pract; 2008 Jan; 62(1):152-6. PubMed ID: 18173815 [TBL] [Abstract][Full Text] [Related]
11. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. Louis F Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980 [TBL] [Abstract][Full Text] [Related]
14. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O; Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402 [TBL] [Abstract][Full Text] [Related]